Lilly's GLP-1 pill seen as superior in head-to-head trial with Novo's oral semaglutide

Core Insights - Eli Lilly's GLP-1 pill has outperformed Novo Nordisk's GLP-1 pill in a phase three trial for type 2 diabetes, with a focus on both diabetes management and weight loss [1][2] - At the highest dose, Lilly's pill reduced blood sugar by 2.2% compared to 1.4% for Novo's oral version, and achieved a weight loss of approximately 9% versus 5% for Novo's product [2] - Lilly used about half the dose for weight loss compared to what Novo plans to use, which may affect real-world results [2][3] - Novo's pill is already available for diabetes at the tested dose, while it seeks approval for a higher dose to treat obesity [3] - Lilly's top scientist indicated that their drug has exceeded street estimates in three out of four studies, and variability in results is expected but not a primary concern for patients [4]